BESPOKE Study of ctDNA Guided Immunotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Cancer
- Melanoma
- Non -Small Cell Lung Cancer
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objective: ? To examine the impact of SIGNATERA™ on clinical decision-making regarding continuation, discontinuation, escalation, or de-escalation of immunotherapy. Secondary Objective: ? To prospectively evaluate the utility of SIGNATERA™ as a tool to detect early evidence of response or pr...
Primary Objective: ? To examine the impact of SIGNATERA™ on clinical decision-making regarding continuation, discontinuation, escalation, or de-escalation of immunotherapy. Secondary Objective: ? To prospectively evaluate the utility of SIGNATERA™ as a tool to detect early evidence of response or progression in patients with advanced solid tumors receiving immune checkpoint inhibitors.
Tracking Information
- NCT #
- NCT04761783
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Alexey Aleshin, MD Natera, Inc.
Get Well Soon